Review of Ocular Immune Privilege in the Year 2010: Modifying the Immune Privilege of the Eye
Review of Ocular Immune Privilege in the Year 2010: Modifying the Immune Privilege of the Eye
复制标题
DOI：
10.3109/09273948.2010.512696
复制
发表时间：
2010-10-01
影响因子：
3.3
通讯作者：
Masli, Sharmila
中科院分区：
文献类型：
--
作者：
Hori, Junko;Vega, Jose L.;Masli, Sharmila
人体内存在免疫特权部位的最初证据是基于遗传上不同的移植组织在眼前房中的长期存活。免疫系统未能在该部位和其他此类部位引发免疫应答构成了免疫赦免状态的标志。角膜移植在临床实践中的显著成功领域无疑与角膜免疫豁免有关。一些研究已经解决了这种现象的调控机制，这涉及到多个分子和细胞途径之间的复杂相互作用。此外，各种转基因小鼠模型的使用促进了关键途径的鉴定，这些途径在被破坏时可以改变眼睛的免疫特权状态。了解这些途径不仅揭示了各种眼部炎症疾病的潜在机制，而且对移植领域和自身免疫治疗具有临床意义。
The original evidence for the existence of immunologically privileged sites in the body was based on the prolonged survival of genetically disparate transplanted tissue in the anterior chamber of the eye. The failure of the immune system to elicit an immune response in this and other such sites constitutes the hallmark of the immune privilege status. The remarkably successful field of corneal transplantation in clinical practice is undoubtedly associated with corneal immune privilege. Several investigations have addressed the regulatory mechanisms governing this phenomenon, which involves a complex interplay between multiple molecular and cellular pathways. Furthermore, the use of various transgenic mouse models has facilitated the identification of critical pathways, which upon disruption can modify the immune privileged status of the eye. Understanding these pathways not only reveals the mechanisms underlying various ocular inflammatory disease conditions, but also has clinical implications for the transplantation field and for the treatment of autoimmunity.